Media Highlights

Media Highlights

Novel combination active in refractory GIST

Nov. 22, 2020

Combination treatment with the investigational, selective KIT inhibitor PLX9486 plus sunitinib (Sutent) was safe and active in patients with relapsed or refractory gastrointestinal stromal tumors (GIST), a small phase I/II study found. Among 18 patients treated with the combination, one achieved a complete response, two had partial responses, and another had an unconfirmed partial response, according to Jonathan Trent, M.D., Ph.D., of the University of Miami Sylvester Comprehensive Cancer Center.

Read the Full article

Tags:   Jonathan Trent, MedPage Today, Sylvester Comprehensive Cancer Center, clinical trial